Curis Company Profile (NASDAQ:CRIS)

Analyst Ratings

Consensus Ratings for Curis (NASDAQ:CRIS) (?)
Ratings Breakdown: 5 Buy Rating(s)
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $5.25 (198.30% upside)

Analysts' Ratings History for Curis (NASDAQ:CRIS)
Show:
DateFirmActionRatingPrice TargetActions
6/13/2016FBR & CoReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/3/2016Robert W. BairdReiterated RatingOutperform$7.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/5/2016Cowen and CompanyInitiated CoverageOutperformView Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/1/2016SunTrust Banks Inc.Initiated CoverageBuy$3.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/29/2016Roth CapitalReiterated RatingBuy$5.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/6/2015Oppenheimer Holdings Inc.Reiterated RatingOutperformView Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/16/2015Stifel NicolausReiterated RatingHoldView Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/27/2014 forward)

Earnings

Earnings History for Curis (NASDAQ:CRIS)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/4/2016        
5/9/2016Q116($0.08)($0.07)$2.30 million$1.70 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/29/2016Q415($0.12)($0.10)$2.98 million$2.10 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/9/2015Q315($0.08)($0.04)$2.82 million$2.00 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/6/2015Q215($0.06)($0.06)$3.50 million$2.10 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/7/2015Q115($0.06)($0.07)$2.27 million$1.17 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/24/2015Q4 14($0.07)($0.07)$2.69 million$2.00 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/10/2014Q314($0.04)($0.06)$4.13 million$1.80 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/7/2014Q214($0.05)($0.02)$3.46 million$4.80 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/8/2014Q114($0.06)($0.06)$1.88 million$1.30 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/20/2014Q413($0.08)($0.05)$1.59 million$1.52 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/5/2013Q313($0.01)($0.02)$6.44 million$7.20 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/5/2013Q2 2013($0.05)($0.02)$4.43 million$5.40 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
4/30/2013Q1 2013($0.05)($0.06)$3.86 million$0.90 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/20/2013Q4 2012($0.08)($0.15)$2.07 million$1.69 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/6/2012Q312($0.08)($0.04)$1.01 million$0.60 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/2/2012($0.05)($0.04)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/8/2012$0.02$0.03ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
10/27/2011($0.07)($0.05)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
7/28/2011($0.07)($0.06)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Curis (NASDAQ:CRIS)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20164($0.08)($0.05)($0.07)
Q2 20164($0.10)($0.05)($0.08)
Q3 20164($0.13)($0.06)($0.10)
Q4 20164($0.12)($0.05)($0.09)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Curis (NASDAQ:CRIS)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Curis (NASDAQ:CRIS)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
5/27/2016Martyn D GreenacreDirectorSell15,000$1.69$25,350.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/26/2016Kenneth I KaitinDirectorSell15,000$1.76$26,400.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/30/2015Daniel R. PasseriDirectorSell14,400$3.01$43,344.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/29/2015Daniel R. PasseriDirectorSell11,200$2.91$32,592.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/28/2015Daniel R. PasseriDirectorSell13,600$2.85$38,760.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/23/2015Daniel R. PasseriDirectorSell48,900$2.78$135,942.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/21/2015Daniel R. PasseriDirectorSell289,000$2.99$864,110.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/27/2014Ali Ph.D. FattaeyCEOBuy62,890$1.60$100,624.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/11/2013Ali Ph.D. FattaeyCOOBuy3,000$2.52$7,560.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/12/2013Michael GrayCFOBuy10,000$2.86$28,600.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/8/2013Kenneth PientaDirectorBuy20,000$2.95$59,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/16/2013James McnabDirectorSell50,000$4.00$200,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/6/2012Daniel R PasseriCEOBuy25,000$3.03$75,750.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Curis (NASDAQ:CRIS)
DateHeadline
07/27/16 03:28 PMTrading the Biotech News: Curis, Inc. (NASDAQ:CRIS), Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) - The Voice Registrar
07/22/16 03:28 PMEarnings Focus and Crowd Sourced Sentiment Review for Curis, Inc. (NASDAQ:CRIS) - TGP
07/22/16 03:28 PMCuris, Inc. (NASDAQ:CRIS) Could Reverse On Near Term Catalysts - Insider Financial
07/19/16 11:14 AMETF’s with exposure to Curis, Inc. : July 19, 2016 -
07/18/16 03:36 PMHow Many Curis, Inc. (NASDAQ:CRIS)'s Analysts Are Bullish? - Consumer Eagle
07/18/16 08:24 AMShares Moving Down on the Week: Curis, Inc. (NASDAQ:CRIS) - Engelwood Daily
07/18/16 08:24 AMNext Weeks Broker Price Targets For Curis, Inc. (CRIS) - Fiscal Standard
07/16/16 05:07 AMShares Experiencing a Downtrend: Curis, Inc. (NASDAQ:CRIS) - TGP
07/15/16 08:56 AMCrowd Rating and Earnings Recap for Curis, Inc. (NASDAQ:CRIS) - Telanagana Press
07/14/16 07:19 AMCuris, Inc. (NASDAQ:CRIS) Wall Street Analyst Recommendation Outlook - Telanagana Press
07/12/16 07:43 AMStock Volatility Focus for: Curis, Inc. (NASDAQ:CRIS) - Engelwood Daily
07/12/16 07:43 AMStock on the Rise for the Quarter: Curis, Inc. (NASDAQ:CRIS) - Engelwood Daily
07/12/16 07:43 AMCuris, Inc. (NASDAQ:CRIS) Earnings Concentration and Analyst Target Watch - Engelwood Daily
07/12/16 07:43 AMTrading Performance and Target Watch for Curis, Inc. (NASDAQ:CRIS) - Press Telegraph
07/12/16 07:43 AMCuris Inc (NASDAQ:CRIS) Institutional Investor Sentiment Trend - Consumer Eagle
07/08/16 03:26 PMCuris, Inc. (CRIS) Updated Price Targets - FTSE News
07/08/16 10:18 AMWall Street Ratings and Target Price Views on Curis, Inc. (NASDAQ:CRIS) - Telanagana Press
07/07/16 08:38 PMStock Moving Up in Trading: Curis, Inc. (NASDAQ:CRIS) - Telanagana Press
07/07/16 08:38 PMHeightened Volatility Check on: Curis, Inc. (NASDAQ:CRIS) - Engelwood Daily
07/06/16 09:13 PMFast Moving Stocks: DuPont Fabros Technology, (NYSE:DFT), Curis, Inc. (NASDAQ:CRIS), Bristol-Myers Squibb ... - KC Register
07/06/16 09:13 PMShare Performance Recap for: Curis, Inc. (NASDAQ:CRIS) - Press Telegraph
07/06/16 09:13 PMStock Rating Watch and Earnings Insight for Curis, Inc. (NASDAQ:CRIS) - Press Telegraph
07/06/16 09:13 PMCuris, Inc. (CRIS) Current Analyst Ratings - Fiscal Standard
07/01/16 08:33 PMShining on Major News: Curis, Inc. (NASDAQ:CRIS), AT&T, Inc. (NYSE:T), Ciber, Inc. (NYSE:CBR), Regeneron ... - KC Register
06/30/16 10:26 AMShare Update and Earnings Review for Curis, Inc. (NASDAQ:CRIS) - Press Telegraph
06/30/16 10:26 AMCuris, Inc. (NASDAQ:CRIS) Company Rating and Target Watch - Telanagana Press
06/27/16 03:24 PMMorning Watch List: Dimension Therapeutics, Inc. (NASDAQ:DMTX), Curis, Inc. (NASDAQ:CRIS), Itau Unibanco (NYSE ... - KC Register
06/27/16 03:24 PMCuris, Inc. (NASDAQ:CRIS) Earnings Glance and Target Price Review - Engelwood Daily
06/26/16 03:05 PMHow Many Curis, Inc. (NASDAQ:CRIS)'s Analysts Are Bullish? - Press Telegraph
06/23/16 02:16 PMNew Broker Ratings For Curis, Inc. (CRIS) - FTSE News
06/22/16 03:34 PMNotable Mover: Curis, Inc. (NASDAQ:CRIS) - iStreetWire
06/22/16 01:05 PMWhat’s so ‘groundbreaking’ about Curis’ new cancer drug that just began human trials? -
06/22/16 08:07 AMCuris May Make A Splash In Immune Checkpoint Inhibition - Seeking Alpha
06/22/16 08:07 AMRecently Issued Stock Ratings For Curis, Inc. (CRIS) - Fiscal Standard
06/21/16 08:08 AMCuris (CRIS) Doses First Patient in CA-170 Phase 1 as Immune Checkpoints Inhibitor
06/21/16 08:08 AMCuris Announces Dosing of First Patient in a Phase 1 Trial of CA-170, the First Oral Small Molecule
06/21/16 06:09 AMCuris Announces Dosing of First Patient in a Phase 1 Trial of CA-170, the First Oral Small Molecule Drug Candidate to Target and Inhibit Immune Checkpoints - [at noodls] - LEXINGTON, Mass., June 21, 2016 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), a biotechnology company focused on the development and commercialization of innovative and effective therapeutics for the ...
06/20/16 03:21 PMInvestors Watch List: The McClatchy Company (NYSE:MNI), Curis, Inc. (NASDAQ:CRIS), Ford Motor Company (NYSE:F ... - KC Register
06/10/16 10:55 AMCuris (CRIS) Announces Presentation of Updated CUDC-907 Phase 1 Data in DLBCL at EHA Meeting
06/09/16 03:22 PMCuris, Inc. (NASDAQ:CRIS) Went Up 2.16%: FMSA Holdings Inc (NYSE:FMSA), Bank of Commerce Holdings ... - KC Register
06/08/16 01:15 PMETF’s with exposure to Curis, Inc. : June 8, 2016 -
06/08/16 11:34 AMAbbVie Inc. (NYSE:ABBV) Went Up 0.45%: Curis, Inc. (NASDAQ:CRIS), Northwestern Corporation (NYSE:NWE ... - KC Register
06/08/16 06:00 AMCuris Announces Oral Presentation of Clinical Data Update from the Phase 1 Study of CUDC-907 at the 21st Congress of the European Hematology Association - [GlobeNewswire] - LEXINGTON, Mass., June 08, 2016-- Curis, Inc., a biotechnology company focused on the development and commercialization of innovative and effective therapeutics for the treatment of cancer, today announced ...
06/06/16 03:13 PMRevisiting My Basket Of Biotech 'Bargains' - Seeking Alpha
06/06/16 03:13 PMCURIS INC. (NASDAQ:CRIS) Financial Condition Compared to S&P 500 - CML News
06/04/16 11:40 AMCuris, Inc. (NASDAQ:CRIS) Stock Update & Estimates - Stock Tick Tock
06/04/16 11:40 AMWill Curis, Inc. (NASDAQ:CRIS) Surprise Analysts? - Investor Newswire
06/03/16 03:31 PMCuris, Inc. (CRIS) Given Outperform Rating at Robert W. Baird - Let Me Know About This
06/01/16 03:32 PMCompany Update (NASDAQ:CRIS): Curis, Inc. Announces FDA Acceptance of Investigational New Drug Application for ... - Smarter Analyst - Company Update (NASDAQ:CRIS): Curis, Inc. Announces FDA Acceptance of Investigational New Drug Application for ...Smarter AnalystCuris, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development and commercialization of innovative and effective therapeutics for the treatment of cancer, today announced that the U.S. Food and Drug Administration (FDA) has accepted ...Curis Says FDA Accepts Investigational New Drug Application For Anti-Cancer Drug (NASDAQ:CRIS)Sonoran Weekly Reviewall 2 news articles »
06/01/16 11:22 AMStock Review and Earnings Check on Curis, Inc. (NASDAQ:CRIS) - HNN - Stock Review and Earnings Check on Curis, Inc. (NASDAQ:CRIS)HNNInvestors and analysts are typically super focused on company earnings numbers when they are reported. Company earnings are a good way to evaluate the company profitability. Currently, sell-side analysts are expecting Curis, Inc. (NASDAQ:CRIS) to ...and more »

Social

About Curis

Curis logoCuris, Inc. is a biotechnology company. The Company is engaged in the development and commercialization of drug candidates for the treatment of human cancers. The Company's drug candidate, CUDC-907, is an orally available, small molecule inhibitor of histone deacetylase (HDAC) and phosphatidylinositol-3-kinase (PI3K) enzymes. Its product pipeline includes CA-170, which is an oral small molecule drug candidate; CA-4948, which is an oral small molecule drug candidate that is designed to inhibit the interleukin-1 receptor-associated kinase 4 (IRAK4) kinase; Erivedge, which is an orally bioavailable small molecule, and is designed to selectively inhibit the Hedgehog signaling pathway; CUDC-427, which is an oral, small molecule Smac mimetic that is designed to promote cancer cell death by antagonizing inhibitor of apoptosis (IAP) proteins, and CUDC-305, which is an oral HSP90 inhibitor for the development in advanced lung cancer.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: Biotechnology
  • Exchange: NASDAQ
  • Symbol: CRIS
  • CUSIP: 23126910
Key Metrics:
  • Previous Close: $1.76
  • 50 Day Moving Average: $1.63
  • 200 Day Moving Average: $1.69
  • P/E Ratio: N/A
  • P/E Growth: 0.00
  • Market Cap: $227.36M
  • Beta: 1.72
  • Current Year EPS Consensus Estimate: $-0.37 EPS
  • Next Year EPS Consensus Estimate: $-0.37 EPS
Additional Links:
Curis (NASDAQ:CRIS) Chart for Wednesday, July, 27, 2016